EMERYVILLE, Calif. and
BOULDER, Colo., Oct. 5, 2021 /PRNewswire/ -- Amyris, Inc.
(Nasdaq: AMRS), a leading synthetic biotechnology company active in
the Clean Health and Beauty markets through its consumer brands,
and a top supplier of sustainable and natural ingredients, today
announced that Amyris has licensed the Onyx genome engineering
platform from Inscripta, a leading gene editing technology company.
Amyris and Inscripta will also explore joint research and
development opportunities to expand the Onyx platform
functionality.
Amyris' product development and formulation team uses a
proprietary Lab-to-Market™ operating system to develop and
scale a growing portfolio of sustainable ingredients. The Onyx
platform automates benchtop biofoundry activity and will bring
greater genetic diversity and value to Amyris' ingredient
development pipeline, complementing Amyris' existing Lab-to-Market
operating system with the goal of improving efficiency and
reducing timelines for the development of future molecules. To
date, Amyris has successfully commercialized 13 sustainable
ingredients, which are formulated in over 20,000 products and used
by over 300 million consumers, demonstrating the growing demand for
sustainable products with clean and effective ingredients.
Automated, high-throughput gene editing is revolutionizing the
writing of genomes the way next-generation sequencing transformed
the reading of genomes. Inscripta is the first company to deliver
an integrated and intuitive benchtop platform that will expand
access to scalable, robust genome engineering and help scientists
develop solutions to some of today's most pressing challenges.
"Amyris has shown the world how new products can be made more
sustainable through biology. Their team has high proficiency in
utilizing cutting-edge technology, and we are excited they will be
pioneering the use of our platform," said Sri Kosaraju, President and CEO of Inscripta.
"We have great regard for Amyris' mission, and we are committed to
seeing the Onyx platform become a substantial contributor to new
clean chemistry products in the future."
"The Onyx platform offers significant potential for generating
greater genetic diversity in our projects, which we expect to lead
to more efficient product innovation," said Sunil Chandran, Senior Vice President of
Research and Development at Amyris. "Inscripta's platform
seamlessly integrates with our own and opens up new experimentation
avenues for our scientists to continue bringing unique bio-based
products to customers. We pride ourselves on continuous innovation
and expect Onyx to help us expand our pipeline, while achieving
lower costs and reducing time to market."
For more information about Amyris visit amyris.com and to
learn about Onyx, visit www.inscripta.com/products.
About Inscripta
Inscripta is a life science technology
company enabling scientists to solve some of today's most pressing
challenges with the first benchtop system for genome editing. The
company's automated Onyx platform, consisting of an
instrument, consumables, assays, and software, makes CRISPR-based
genome engineering accessible to any research lab. Inscripta
supports its customers around the world from facilities in
Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark. To learn more,
visit Inscripta.com and follow @InscriptaInc.
About Amyris
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris is proud to own
and operate a family of consumer brands - all built around its No
Compromise® promise of clean ingredients: Biossanceâ clean
beauty skincare, Pipetteâ clean baby skincare, Purecane™, a
zero-calorie sweetener naturally derived from sugarcane,
Terasanaâ clean skincare treatment, Costa Brazil luxury
skincare, OLIKA hygiene and wellness, Rose Inc.™ clean color
cosmetics and JVN™ clean haircare. For more information, please
visit http://www.amyris.com.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette,
Purecane, Terasana, Rose Inc. and Lab-to-Market are trademarks or
registered trademarks of Amyris, Inc. in the U.S. and/or other
countries.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among
other things, statements regarding Amyris' expectation of exploring
additional research and development opportunities with Inscripta in
the future and its expectation that Onyx will help Amyris expand
its pipeline while achieving lower costs and reducing time to
market. These statements are based on management's current
expectations and actual results and future events may differ
materially due to risks and uncertainties, including risks related
to any delays or failures in the successful launch of a clean
skincare brand; potential delays or failures in development,
production, regulatory approval and commercialization of products,
risks related to Amyris' reliance on third parties; Amyris'
liquidity and ability to fund operating and capital expenses; and
other risks detailed from time to time in filings Amyris makes with
the Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a result
of new information, future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-partners-with-inscripta-to-enhance-development-of-sustainable-ingredients-using-the-onyx-genome-engineering-platform-301391722.html
SOURCE Amyris, Inc.